<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03296202</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/04</org_study_id>
    <nct_id>NCT03296202</nct_id>
  </id_info>
  <brief_title>Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV</brief_title>
  <acronym>AquiVIH-NA</acronym>
  <official_title>Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV: The ANRS CO3 Aquitaine Cohort - AquiVIH-NA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Agency for Research on AIDS and Viral Hepatitis (ANRS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>French Ministry of Health through the COREVIH Aquitaine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV infection is now a chronic disease in countries where antiretroviral treatments (ART) are&#xD;
      largely available. Long-term follow-up is required to describe and understand the evolution&#xD;
      of morbidities and complications as well as new treatments side effects.&#xD;
&#xD;
      The main objective of the cohort is to describe and study the evolution of HIV infection in&#xD;
      ART-treated individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The survival of people living with HIV (PLHIV) taking antiretroviral therapy (ART) is now&#xD;
      close to what is reported in the general population in northern countries. However, PLHIV&#xD;
      experience an increased risk of morbidities that the ANRS CO3 Aquitaine Cohort has largely&#xD;
      contributed to describe in the last years. Among contributing factors to this excess of&#xD;
      morbidity, immune suppression, immune activation, and exposition to cardiovascular and cancer&#xD;
      risk factors as well as ageing represent possible intervention targets. Long-term follow-up&#xD;
      is required to describe and understand the evolution of morbidities and complications as well&#xD;
      as ART side effects.&#xD;
&#xD;
      Moreover, the global evaluation of health in PLHIV, including psychiatric, neurologic and&#xD;
      social determinants and not only biomedical determinants represents one of the public health&#xD;
      challenges of the next decade in the field of HIV infection.&#xD;
&#xD;
      The aim of the present study is to study the emerging morbidity occurring during the course&#xD;
      of HIV infection in people treated with ART as well as to describe the tolerance and efficacy&#xD;
      of new available ART regimens.&#xD;
&#xD;
      The follow-up of patients will be performed according to national guidelines. Demographic,&#xD;
      clinical, biological and therapeutic data will be captured at each patient's hospital contact&#xD;
      according to a standardized questionnaire.&#xD;
&#xD;
      All events occurring during the course of clinical management will be prospectively&#xD;
      registered in the database according to the ICD 10th revision. A biobank will be collected&#xD;
      from every consenting PLHIV at inclusion in the cohort and then every two years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Socio-demographic characteristics of people living with the HIV</measure>
    <time_frame>Each 12 months from baseline for 4 years (M48)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV infection characteristics of people living with the HIV</measure>
    <time_frame>Each 12 months from baseline for 4 years (M48)</time_frame>
    <description>group of infection, stage of infection, duration since first serology positive, CD4 nadir, last CD4 measurement, CD4 / CD8 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comorbidities of people living with the HIV</measure>
    <time_frame>Each 12 months from baseline for 4 years (M48)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>co-infections of people living with the HIV</measure>
    <time_frame>Each 12 months from baseline for 4 years (M48)</time_frame>
    <description>Hepatitis B, Hepatitis C, cytomegalovirus infection...</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutics description</measure>
    <time_frame>Each 12 months from baseline for 4 years (M48)</time_frame>
    <description>naïve / treated status, dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>virological responses</measure>
    <time_frame>Each 12 months from baseline for 4 years (M48)</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">7200</enrollment>
  <condition>HIV Infections</condition>
  <condition>Antiretroviral Agents</condition>
  <arm_group>
    <arm_group_label>HIV patients</arm_group_label>
    <description>4500 patients infected with HIV-1</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients infected with HIV-1 (PLHIV)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged over 18 years old.&#xD;
&#xD;
          -  Confirmed HIV infection&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV-2 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda WITTKOP, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>ISPED - CHU de Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fabrice BONNET, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabrice BONNET, Prof</last_name>
    <phone>(0)5 56 79 58 26</phone>
    <phone_ext>+33</phone_ext>
    <email>fabrice.bonnet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier LELEUX</last_name>
    <phone>(0)5 57 57 45 44</phone>
    <phone_ext>+33</phone_ext>
    <email>Olivier.Leleux@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>service de médecine interne - CH d'Agen</name>
      <address>
        <city>Agen</city>
        <zip>47923</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick RISPAL, MD</last_name>
      <email>rispalp@ch-agen.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick RISPAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine interne - CH d'Angoulême</name>
      <address>
        <city>Angoulême</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès RICHE, MD</last_name>
      <email>agnes.riche@ch-angouleme.fr</email>
    </contact>
    <investigator>
      <last_name>Agnès RICHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de maladies infectieuses - CH de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc-Olivier VAREIL, MD</last_name>
      <email>movareil@ch-cotebasque.fr</email>
    </contact>
    <investigator>
      <last_name>Marc-Olivier VAREIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine inter et maladies infectieuses - Hopital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick MERCIE, Prof</last_name>
      <email>patrick.mercie@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick MERCIE, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne et maladies infectieuses - Hôpital Saint-André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice BONNET, Prof</last_name>
      <email>fabrice.bonnet@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice BONNET, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de maladies infectieuses et médecine tropicale - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MALVY Denis, Prof</last_name>
      <email>denis.malvy@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Denis MALVY, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de maladies infectieuses et médecine tropicale - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier NEAU, Prof</last_name>
      <email>didier.neau@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Didier NEAU, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de maladies infectieuses et médecine tropicale - Hôpital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DUPON Michel, Prof</last_name>
      <email>michel.dupon@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>DUPON Michel, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service D'Urgences Pédiatriques</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille RUNEL-BELLIARD, MD</last_name>
      <email>camille.runel@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Camille RUNEL-BELLIARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>médecine interne - CH de Châtellerault</name>
      <address>
        <city>Châtellerault</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine ELSENDOORN, MD</last_name>
      <email>antoine.elsendoorn@ghnv.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine ELSENDOORN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne et maladies infectieuses - CH de Dax</name>
      <address>
        <city>Dax</city>
        <zip>40107</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann GERARD, MD</last_name>
      <email>gerardy@ch-dax.fr</email>
    </contact>
    <investigator>
      <last_name>Yann GERARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine Interne - CH de Jonzac</name>
      <address>
        <city>Jonzac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry PASDELOUP, MD</last_name>
      <email>thierry.pasdeloup@ch-jonzac.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry PASDELOUP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne - CH d'Arcachon</name>
      <address>
        <city>La Teste-de-Buch</city>
        <zip>33260</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carine COURTAULT, MD</last_name>
      <email>carine.courtault@ch-arcachon.fr</email>
    </contact>
    <investigator>
      <last_name>Carine COURTAULT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne - CH de Libourne</name>
      <address>
        <city>Libourne</city>
        <zip>33505</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene FERRAND, MD</last_name>
      <email>helene.ferrand@ch-libourne.fr</email>
    </contact>
    <investigator>
      <last_name>Sten DE WITTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Helene FERRAND, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne - CH de Mont de Marsan</name>
      <address>
        <city>Mont-de-Marsan</city>
        <zip>40024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hajnal-Gabriela ILLES, MD</last_name>
      <email>gabriela.illes@ch-mdm.fr</email>
    </contact>
    <investigator>
      <last_name>Hajnal-Gabriela ILLES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne - CH d'Orthez</name>
      <address>
        <city>Orthez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann GERARD, MD</last_name>
      <email>gerardy@ch-dax.fr</email>
    </contact>
    <investigator>
      <last_name>Yann GERARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne et maladies infectieuses - CH de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric MONLUN, MD</last_name>
      <email>eric.monlun@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Eric MONLUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne et maladies infectieuses - CH de Périgueux</name>
      <address>
        <city>Perigueux</city>
        <zip>24019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe LATASTE, MD</last_name>
      <email>philippe.lataste@ch-perigueux.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe LATASTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de médecine interne et maladies infectieuses - Groupe hospitalier Sud</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <email>jean-francois.viallard@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Luc PELLEGRIN, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine interne et Maladies Infectieuses - CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaël LE MOAL, MD</last_name>
      <email>gwenael.le-moal@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Gwenaël LE MOAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine interne - CH de Royan</name>
      <address>
        <city>Royan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe MOTTAZ, MD</last_name>
      <email>philippe.mottaz@ch-royan.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe MOTTAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine Interne - CH de Saint-Jean-D'Angely</name>
      <address>
        <city>Saint-Jean-d'Angély</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry PASDELOUP, MD</last_name>
      <email>thierry.pasdeloup@ch-angely.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry PASDELOUP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médecine Interne - CH de Saintonge</name>
      <address>
        <city>Saintes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry PASDELOUP, MD</last_name>
      <email>thierry.pasdeloup@ch-saintonge.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry PASDELOUP, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>service de maladies infecteieuses - CH Saint-Cyr</name>
      <address>
        <city>Villeneuve sur Lot</city>
        <zip>47307</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle CHOSSAT, MD</last_name>
      <email>isabelle.chossat@ch-stcyr.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle CHOSSAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>September 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2017</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>cohort studies</keyword>
  <keyword>antiretroviral treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03296202
org study id: CHUBX 2016/04
nct id: NCT03296202
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
HIV infection is now a chronic disease in countries where antiretroviral treatments (ART) are
      largely available. Long-term follow-up is required to describe and understand the evolution
      of morbidities and complications as well as new treatments side effects.

      The main objective of the cohort is to describe and study the evolution of HIV infection in
      ART-treated individuals.
The survival of people living with HIV (PLHIV) taking antiretroviral therapy (ART) is now
      close to what is reported in the general population in northern countries. However, PLHIV
      experience an increased risk of morbidities that the ANRS CO3 Aquitaine Cohort has largely
      contributed to describe in the last years. Among contributing factors to this excess of
      morbidity, immune suppression, immune activation, and exposition to cardiovascular and cancer
      risk factors as well as ageing represent possible intervention targets. Long-term follow-up
      is required to describe and understand the evolution of morbidities and complications as well
      as ART side effects.

      Moreover, the global evaluation of health in PLHIV, including psychiatric, neurologic and
      social determinants and not only biomedical determinants represents one of the public health
      challenges of the next decade in the field of HIV infection.

      The aim of the present study is to study the emerging morbidity occurring during the course
      of HIV infection in people treated with ART as well as to describe the tolerance and efficacy
      of new available ART regimens.

      The follow-up of patients will be performed according to national guidelines. Demographic,
      clinical, biological and therapeutic data will be captured at each patient's hospital contact
      according to a standardized questionnaire.

      All events occurring during the course of clinical management will be prospectively
      registered in the database according to the ICD 10th revision. A biobank will be collected
      from every consenting PLHIV at inclusion in the cohort and then every two years.
observational model: Cohort
time perspective: Prospective
measure: Socio-demographic characteristics of people living with the HIV
time frame: Each 12 months from baseline for 4 years (M48)
measure: HIV infection characteristics of people living with the HIV
time frame: Each 12 months from baseline for 4 years (M48)
description: group of infection, stage of infection, duration since first serology positive, CD4 nadir, last CD4 measurement, CD4 / CD8 ratio
measure: comorbidities of people living with the HIV
time frame: Each 12 months from baseline for 4 years (M48)
measure: co-infections of people living with the HIV
time frame: Each 12 months from baseline for 4 years (M48)
description: Hepatitis B, Hepatitis C, cytomegalovirus infection...
measure: Therapeutics description
time frame: Each 12 months from baseline for 4 years (M48)
description: naïve / treated status, dosage
measure: virological responses
time frame: Each 12 months from baseline for 4 years (M48)
arm group label: HIV patients
description: 4500 patients infected with HIV-1
Blood sampling
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Linda WITTKOP, MD, PhD
role: Study Chair
affiliation: ISPED - CHU de Bordeaux
last name: Fabrice BONNET, Prof
role: Principal Investigator
affiliation: University Hospital, Bordeaux
last name: Fabrice BONNET, Prof
phone: (0)5 56 79 58 26
phone ext: +33
email: fabrice.bonnet@chu-bordeaux.fr
last name: Olivier LELEUX
phone: (0)5 57 57 45 44
phone ext: +33
email: Olivier.Leleux@u-bordeaux.fr
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
facility: 
status: Not yet recruiting
contact: 
investigator: 
country: France
responsible party type: Sponsor
mesh term: HIV Infections